ArticleTranslational lung cancer research2026
Synergistic effects and molecular mechanisms of pirfenidone combined with EGFR-TKIs in non-small cell lung cancer.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality globally. While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as osimertinib (OS) and afatinib (AF), have markedly improved clinical outcomes, their efficacy is significantly hindered by the development of acquired resistance. Emerging evidence suggests that p38γ is involved in the progression of NSCLC and the emergence of resistance to EGFR-TKIs. However, whether the p38γ inhibitor pirfenidone (PFD) can enhance the sensitivity of NSCLC to EGFR-TKIs remains unclear. This study aims to evaluate the synergistic antitumor effects of PFD in combination with OS or AF and to elucidate the underlying molecular mechanisms. Methods: EGFR-mutant NSCLC cell lines (PC9 and HCC827) and their OS-resistant derivatives (HCC827 OR) were utilized to evaluate cell proliferation by Cell Counting Kit-8 (CCK-8) assays and colony formation experiments. Western blotting was performed to analyze the expression of p38γ, proteins within the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway, and autophagy-related markers. Drug interactions were assessed using the SynergyFinder platform. Autophagic flux was investigated via a dual-fluorescent adenovirus (mRFP-GFP-LC3) and further validated using the autophagy inhibitor bafilomycin A1. Additionally, an HCC827 nude mouse xenograft model was employed for Results: The combination of PFD with either OS or AF exhibited significant synergistic antitumor effects in both Conclusions: PFD enhances the efficacy of EGFR-TKIs through a dual mechanism: first, by specifically inhibiting the p38γ-mediated PI3K/AKT/mTOR signaling pathway, and second, by activating a p38γ-independent autophagy pathway. The activation of the p38γ-mediated PI3K/AKT/mTOR pathway may represent a key mechanism underlying OS resistance. This study provides the first evidence that PFD can restore drug sensitivity in OS-resistant cells, offering valuable experimental support for its potential clinical application as an EGFR-TKI sensitizer and a therapeutic strategy to overcome resistance in targeted cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.